3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big-name players and clinical-stage companies alike.

D&D Pharmatech Announces The Lancet Gastroenterology & Hepatology Publication of Phase 2 Data Demonstrating Rapid, Weight-Independent Activity of Zabopegdutide (DD01) in MASLD/MASH

D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced the publication of 12-week ...

MASH therapy enters a more competitive era

Rezdiffra is no longer the only option; it is the incumbent to beat, and it is being approached from two different ...
The American Journal of Managed Care

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...